Human Albumin Baxalta

Human Albumin Baxalta is a sterile solution for injection that contains human serum albumin as the active ingredient. It is supplied in an unspecified strength and is administered intravenously. The product is classified as a plasma protein and is prescribed as a volume expander to restore plasma oncotic pressure in clinical settings across the European Union and used for patients with hypovolemia, burns, or hypoalbuminemia.

Human Albumin Baxalta is indicated for several conditions where plasma volume or albumin levels need rapid restoration.

- Treatment of hypovolemia due to blood loss, trauma, or surgery. - Management of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Supportive care in patients with extensive burns to maintain intravascular volume. - Adjunct therapy in circulatory shock when conventional fluids are insufficient. - Volume replacement during cardiac surgery or extracorporeal circulation procedures.

Adverse reactions to Human Albumin Baxalta are generally infrequent but can range from mild to severe.

Common: - Transient fever or chills. - Mild hypotension or hypertension. - Headache or dizziness. - Nausea or vomiting. - Localized erythema or pruritus at the infusion site. - Flushing or warmth sensation. - Mild dyspnea.

Serious: - Anaphylactic or anaphylactoid reactions. - Acute hemolysis. - Severe hypotension leading to shock. - Pulmonary edema. - Thromboembolic events such as deep vein thrombosis. - Renal dysfunction or failure. - Severe allergic skin rash (urticaria).

Clinicians should evaluate patient-specific factors before initiating therapy with Human Albumin Baxalta.

- Assess baseline serum albumin level and overall fluid status before infusion. - Use caution in patients with heart failure, pulmonary edema, or uncontrolled hypertension. - Monitor vital signs and fluid balance throughout the infusion to detect overload. - Check renal and hepatic function, especially in chronic kidney or liver disease. - Infuse slowly according to recommended rate to minimize cardiovascular stress. - Review any prior allergic reactions to albumin or blood products before administration.

Human Albumin Baxalta may interact with other agents that affect fluid balance, coagulation, or immune response.

Avoid: - Concurrent use of high‑dose diuretics that may precipitate hypovolemia. - Simultaneous administration of other plasma expanders without careful monitoring. - Use with agents that cause severe vasodilation, such as high‑dose nitroprusside, without volume assessment.

Use with caution: - Co‑administration with anticoagulants (e.g., heparin, warfarin) due to potential changes in plasma protein binding. - Combination with nephrotoxic drugs, as fluid shifts may affect renal perfusion. - Concurrent use of immunosuppressants may mask allergic reactions. - Overlap with other colloid solutions (e.g., hydroxyethyl starch) requires close monitoring of oncotic pressure. - Use with caution in patients receiving vasoactive agents that may alter hemodynamics.